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The clinical effectiveness of using a predictive algorithm to
guide antidepressant treatment in primary care (PReDicT): an
open-label, randomised controlled trial
Michael Browning1,2,3, Amy C. Bilderbeck1, Rebecca Dias4, Colin T. Dourish 1,4, Jonathan Kingslake4, Jürgen Deckert5,
Guy M. Goodwin 2, Philip Gorwood6,7, Boliang Guo8, Catherine J. Harmer 2, Richard Morriss8, Andreas Reif 9, Henricus G. Ruhe10,11,
Anneke van Schaik12, Judit Simon2,13, Victor Perez Sola14, Dick J. Veltman15, Matilde Elices14, Anne G. Lever12, Andreas Menke 5,16,
Elisabetta Scanferla17, Michael Stäblein9 and Gerard R. Dawson1,4
Depressed patients often do not respond to the first antidepressant prescribed, resulting in sequential trials of different
medications. Personalised medicine offers a means of reducing this delay; however, the clinical effectiveness of personalised
approaches to antidepressant treatment has not previously been tested. We assessed the clinical effectiveness of using a predictive
algorithm, based on behavioural tests of affective cognition and subjective symptoms, to guide antidepressant treatment. We
conducted a multicentre, open-label, randomised controlled trial in 913 medication-free depressed patients. Patients were
randomly assigned to have their antidepressant treatment guided by a predictive algorithm or treatment as usual (TaU). The
primary outcome was the response of depression symptoms, defined as a 50% or greater reduction in baseline score of the QIDS-
SR-16 scale, at week 8. Additional prespecified outcomes included symptoms of anxiety at week 8, and symptoms of depression
and functional outcome at weeks 8, 24 and 48. The response rate of depressive symptoms at week 8 in the PReDicT (55.9%) and
TaU (51.8%) arms did not differ significantly (odds ratio: 1.18 (95% CI: 0.89–1.56), P= 0.25). However, there was a significantly
greater reduction of anxiety in week 8 and a greater improvement in functional outcome at week 24 in the PReDicT arm. Use of the
PReDicT test did not increase the rate of response to antidepressant treatment estimated by depressive symptoms but did improve
symptoms of anxiety at week 8 and functional outcome at week 24. Our findings indicate that personalisation of antidepressant
treatment may improve outcomes in depressed patients.
Neuropsychopharmacology (2021) 0:1–8; https://doi.org/10.1038/s41386-021-00981-z
INTRODUCTION
Depression, usually accompanied by anxiety, is the leading cause
of years lived with disability worldwide [1]. It results in a marked
functional impairment of patients and, consequently, a huge
economic impact [2]. While a large number of medications have
been found to reduce symptoms of depression [3], as many as
50% of patients do not respond to the initial medication
prescribed [4] and require sequential trials of different treatments.
Further, appreciable subjective improvement is often only
apparent after four to six weeks of treatment, prolonging the
duration of each treatment trial [5, 6]. In practice, the delay
between trials of different treatments is longer than this [7]. As a
result, there is often a significant delay between the decision that
a patient requires treatment and starting that patient on an
effective antidepressant.
Personalised medicine, using the characteristics of a patient to
select the most effective treatment, offers one route by which this
delay may be reduced [8]. A number of demographic, clinical,
cognitive and physiological measures, collected either at baseline
[9–14] or after a brief initial period of treatment [15–17], have
been reported to predict clinical response. However, the crucial
next step in the development of a personalised approach to
treatment, which has yet to be taken for drugs for depression, is to
test whether using these factors to guide treatment selection has
a clinically meaningful impact on outcomes [8].
In previous work, we have described the development and
validation of a predictive algorithm (the PReDicT test) based on
measures of affective processing bias and symptoms of depres-
sion [15]. Affective processing bias describes the tendency for
individuals to preferentially remember, interpret or pay attention
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to positive relative to negative information [18]. Depressed
patients, for example, display a negative bias, interpreting
ambiguous facial expressions as being less happy than non-
depressed participants [18]. Antidepressant medications act very
early in the course of treatment to induce a positive processing
bias [18–20]. This early cognitive effect is seen across different
classes of antidepressant [21] and is associated with improved
treatment response [22]. In our classifier development work, we
used measures of affective processing and symptoms of depres-
sion after one week of antidepressant treatment to predict
response at 6 weeks with an accuracy of 60% [15].
In the PReDicT trial [23], we tested the clinical effectiveness of
using the PReDicT algorithm to guide treatment versus unguided
care in a large sample of patients presenting with symptoms of
depression and anxiety. Recruitment was predominately from
primary care in five European healthcare systems. Patients were
randomised to have treatment guided by the algorithm, which
could prompt the clinician to make early changes in treatment
[24], or to treatment as usual (TaU), and were followed up for a
year after randomisation.
PATIENTS AND METHODS
Study design and patients
The PReDicT trial was a two-arm, multisite, open-label, randomised
controlled trial of a medical device (the PReDicT test) in patients
from five European countries (UK, Spain, Germany, France and the
Netherlands, see Supplementary Materials for more information
on the recruitment centres) [23]. Patients were eligible for
inclusion if they were aged between 18 and 70 and were deemed
by their treating clinician to require initiation of treatment with a
selective serotonin reuptake inhibitor (SSRI, excluding fluoxetine,
due to its longer half-life) for the treatment of a depressive
episode. Exclusion criteria included current treatment with an
antidepressant, a previous history of mania or a presentation that
required immediate referral to a separate service (e.g., significant
suicidal intent requiring enhanced care).
All patients provided written informed consent. Ethics approval
was obtained from the National Research Ethics Service committee,
North East York (16/NE/0095), Ile de France Ethics Committee
(MDPT-RIAL/MM/2016-AO1054-47), Medisch Ethische Toetsingcom-
missie VU Medisch Centrum (2016.294 NL58027.029.16), CEIC Par de
Salut Mar (2016/6795/I), Ethik Komission der Universitat Wurzburg
(117/16-sc) and Ethik Kommission des Fachbereichs Medizin,
Universitatsklinikum der Goethe Universitat Frankfurt (34/17B).
Randomisation and masking
Patients were randomised to have antidepressant treatment
guided by the PReDicT test (PReDicT group) or to receive
treatment as usual (TaU group) using a 1:1 ratio across the study.
Following recruitment by the treating clinician at study sites, a
study researcher registered each patient onto the online electro-
nic patient-reported outcome system (P1vital® ePRO system) that
performed the randomisation. Randomisation was stratified by
study country and minimised by (a) gender (male/female), (b) age
(18–44 and 45–70) and (c) baseline depression severity (mild/
moderate, defined as a score of ≤15, and severe/very severe,
defined as a score of >15) using the standardised severity cut-offs
from the 16 items, self-report version of the Quick Inventory of
Depressive Symptoms (QIDS-SR-16) questionnaire [25]. Patients
were not informed of the group they had been randomised into
but could deduce this from the information they received during
the study (only patients in the PReDicT arm would be asked
to change medication based on the results of their PReDicT test).
The treating clinician and raters for the Montgomery–Åsberg
Depression Rating Scale (MADRS) [26] were aware of patients’
randomisation group for the same reason. The trial statistician was
blinded to group allocation. This is therefore an open-label study.
All treatment decisions were made by the treating clinician, not by
study researchers.
The first 110 patients were assigned to the PReDicT arm or the
TaU arm in a 1:10 ratio. During this phase, minimisation was not
used. The first 67 patients recruited into the TaU arm were used
to refine the predictive algorithm (N.B. clinical response at week 8
was required to retrain the algorithm and this was available at the
time for only 67 of the 100 patients randomised to the TaU arm).
The rationale for this was that the algorithm had previously been
trained using data from UK-based patients who had only received
citalopram, raising the possibility that it was not representative of
data from this study in which patients were recruited from across
Europe and received a range of treatments. In order to address
this concern, the algorithm was retrained (see below for details)
using more representative participants from the TaU arm. NB the
primary analysis is reported for all patients, with a sensitivity
analysis reported only for those patients recruited following the
algorithm update in the supplementary results.
Procedures
Following recruitment, patients were prescribed an SSRI (exclud-
ing fluoxetine) by their treating clinician but did not initiate the
treatment until the baseline assessment was completed. At
the time of prescription, the treating clinician was not aware of
the patients’ randomisation group. The baseline assessment took
place within 7 days of antidepressant prescription and consisted
of self-reported questionnaires and the affective processing task,
both administered by the ePRO system, and an observer-rated
assessment of depressive symptoms. The affective processing task
[27] consisted of pictures of faces displaying a range of emotional
expressions (sad, happy, fearful, surprise, disgust, anger and
neutral), at ten different intensities (10–100% in steps of 10%) that
were displayed for 500ms each. Patients were asked to categorise
the expression of the faces as one of the emotions listed above.
The predictive algorithm was based on changes in the perfor-
mance of the affective processing task as well as individual item
scores from the QIDS-SR-16 questionnaire between the baseline
session and weeks 1 and 2. Patients were asked to initiate their
prescribed treatment, and report this on the ePRO system, after
completion of the baseline session.
All patients repeated the affective processing task and QIDS-SR-
16 self-report questionnaire 1 week (7–9 days) after treatment
initiation. At this point, the treating clinicians of patients in the
PReDicT arm were informed of the result of the PReDicT test and,
if the prediction was non-response, were advised to adjust the
patient’s antidepressant treatment. Where patietns were predicted
to be responding, clinicians were advised not to alter treatment.
Clinicians were encouraged to come to a collaborative decision on
prescribing based on the result of the PReDicT test and other
clinically relevant information, e.g., side effects and patient
preferences. For patients in the TaU arm, clinicians did not receive
the results of the PReDicT test and were asked to manage patients
as per normal practice (i.e., alter treatment in response to lack of
efficacy and/or side effects). Those patients in the PReDicT arm
predicted not to be responding repeated the PReDicT test at week
2 (a further 7–9 days), with the result of the prediction again
provided to their clinician. Thereafter, the PReDicT test was not
administered again and all patients were treated according to
local prescribing guidelines. All patients were asked to complete
the QIDS-SR-16 weekly, using the ePRO system until week 8, at
which point patients attended the study centre to repeat the
baseline assessments (other than the affective processing task).
Following this, patients completed remote assessments using the
ePRO system of the QIDS-SR-16 monthly to one year and the SAS-
screener, the 14-item “screener” form from the social adjustment
scale (SAS scale [28]), at months 6 and 12. Adverse events were
collected during study visits (until week 8). Adverse events were
not collected during the remote follow-up phase.
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The PReDicT test used a support vector machine [29] to provide
a binary prediction (patient responding/not responding to
treatment) based on the change of depressive symptoms
(measured using the QIDS-SR-16) and change in the performance
of the effective bias task over the first one and 2 weeks of
treatment. A detailed description of the development of the test is
provided here [15]. In brief, the algorithm used in the current
study (including the refinement step after 67 patients had been
recruited) selected the top 50% predictive features derived from
changes in the face-processing task and the QIDS-SR-16, with the
C-parameter selection based on the leave-one-out accuracy within
the training sample. Data from a subset of patients in the TaU arm
were used to provide an out-of-sample accuracy in the report of
the classifier development [15], with no other overlap between
study participants.
Clinicians were asked to use antidepressants and doses that
were consistent with local prescribing guidelines. In response to
predictions of non-response, clinicians were asked to consider
either (a) increasing the dose of the antidepressant, (b) changing
the antidepressant or (c) augmenting the antidepressant (e.g.,
adding mirtazapine to ongoing treatment with an SSRI).
Outcomes
The primary outcome was treatment response at week 8. The
response was defined as a 50% or greater reduction of the
baseline QIDS-SR-16 score. Additional prespecified outcomes
were; change in anxiety scores at week 8 (measured using the
Generalised Anxiety Disorder Assessment, seven-item version,
GAD-7 [30]), remission of depression at week 8 (defined as QIDS-
SR-16 score of ≤ 5), change in the individual item scores from the
QIDS-SR-16 measuring restlessness and sadness at week 8, change
in symptoms of depression (treated as a continuous variable)
across 12 months (measured using QIDS-SR-16), change in
observer- reported symptoms of depression (treated as dichot-
omous response and as a continuous variable and measured using
the MADRS at week 8 and change in functional outcome across
12 months (measured using the SAS-screener). Patients also
completed detailed health economic, acceptability and cognitive
functioning measures that will be reported separately [23].
Statistical analysis
The sample size was determined based on a minimum clinically
relevant effect size (i.e., the difference in effect size between the
TaU and PReDicT arms), which was set at 10% for the primary
outcome. Setting alpha (two-tailed) at 0.05 and power at 80% with
the estimated baseline response rate of 40% [15] indicated that a
total sample size of 776 participants with primary outcome data
(388 per group) would be required. The estimated attrition rate for
the study was 35%, suggesting a total recruitment target of 1200.
In practice, attrition was substantially lower (15%) than expected,
meaning that the target sample was achieved following the
recruitment of 913 patients.
Analyses and reporting were in line with CONSORT guidelines
and were described in a pre-published protocol [23] and statistical
analysis plan (SAP, DOI: 10.5281/zenodo.1235968). Efficacy ana-
lyses and outcomes were defined in the protocol and SAP and
were not changed during the course of the study.
Intention-to-treat analyses were used, the population analysed
was all participants randomised to the trial. The primary analysis
used multilevel logistic regression with age, gender and baseline
depression score included as covariates and country as higher-
level units to quantify the effect of group membership on
treatment response as an odds ratio (OR) with 95% confidence
interval. Missing outcomes were imputed by multiple imputations
under the missing at random assumption. To determine the
influence of ‘data missingness’ on the primary analysis, a
sensitivity analysis was conducted using only the observed data.
Additional categorical outcomes were analysed in a similar
manner as the primary outcome. Continuous additional outcomes
were analysed using a multilevel linear regression with categorical
time and time x arm interactions included as additional covariates
when there was more than one follow-up time point.
Non-prespecified exploratory mediation analysis is also pre-
sented. This analysis sought to test the potential mediating
relationship between the observed differences between groups.
Methodological details of this analysis are provided in the Supple-
mentary Methods. The study was overseen by an independent
data-monitoring committee. All analyses were performed in
STATA version 16. The study was registered with clinicaltrials.
gov, reference NCT02790970 before study commencement, with
no significant changes to the methodology being made during
the course of the study.
RESULTS
Between July 26, 2016 and September 28, 2018, we recruited and
randomised 913 patients, 460 (50%) to the PReDicT arm and 453
(50%) to the TaU arm (Fig. 1). The trial achieved its recruitment
target with complete data for the primary analysis available for
778 patients (PReDicT 392 patients, TaU 386 patients). Approxi-
mately half were recruited in the United Kingdom, with the
remainder recruited throughout the other European countries. A
detailed summary of recruitment and retention by country is
provided in the supplementary materials.
The baseline characteristics were similar between groups
(Table 1). Recruited participants were largely white (90%), with
more females (62%) than males (38%), reflecting the usual 2:1
gender ratio in depression. The mean age was approximately 40
years, with the age range spanning from the minimum to
maximum permitted (18–70). The mean QIDS-SR-16 score was
15, on the borderline between moderate and severe depression
[25]. The mean anxiety score was 13.5 (GAD-7), similar to previous
outpatient clinical samples [31], and functional level scores were
63 (SAS-SR screener), which is also similar to previous samples of
depressed primary care patients [28].
Patient retention for the primary outcome at week 8 was 85%.
Retention at the end of follow-up (month 12) was 50%, with no
statistical difference between groups for either figure. Clinician
behaviour, in terms of prescribed medication, was influenced by
the results of the PReDicT test in the PReDicT arm with 65% of
patients, who were predicted not to be responding, having their
medication altered within the first 2 weeks, compared to 15% who
were predicted to be responding (20 and 16%, respectively, in the
TaU group, see Supplementary Materials for more details).
Response rates estimated with QIDS-SR-16 at week 8 were
55.9% (95% CI: 48.52–63.05) for the PReDicT arm and 51.8 (95% CI:
44.44–59.08) for the TaU arm. After adjustment for baseline scores
and stratification variables, the odds ratio of the difference
between arms was not significant at 1.18 (95% CI: 0.89, 1.56), P=
0.250 (Table 2). There was no difference in rates of remission of
depressive symptoms using either the QIDS-SR-16 or the MADRS
scales or in the QIDS-SR-16 items measuring sadness and
restlessness (Table 2).
We did find evidence of a greater reduction in symptoms of
anxiety in the PReDicT arm than the TaU arm. There was also a
significantly greater improvement in functional outcomes as
measured using the SAS-SR screener at month 6, with the
difference becoming non-significant by month 12 (Table 3).
Exploratory analysis
The finding that patients in the PReDicT group had lower anxiety
at week 8 and improved functional outcome at month 6 suggested
that the improved functional outcome may have arisen due to
the earlier effects on anxiety. We tested this possibility using a
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non-prespecified exploratory mediation analysis that demon-
strated a significant mediation effect −0.47 (0.24), P= 0.048.
Further details of this analysis are included in the Supplementary
Materials.
We recorded 158 adverse events in the PReDicT group and 167
in the TaU group during the study; the most common type of
event in both groups was gastrointestinal disorder. Of these
events, two were judged to be potentially related to the PReDicT
test (both were headaches after completing the test). In total, five
serious adverse events were recorded in the PReDicT group and
8 in the TaU group, none of which were related to the PReDicT
test. Three serious adverse events involved attempted suicide
(all in the TaU group) and one hospitalisation because of increased
suicidality (in TaU group). There were no deaths recorded.
DISCUSSION
In our primary analysis, we did not find an improved response of
depressive symptoms to antidepressant treatment in the PReDicT
group at week 8. Analyses of additional prespecified outcomes
confirmed no improvement in recovery from depression, or
depressive symptom level, but did show a greater reduction in
symptoms of anxiety, at week 8 and of functional outcomes at
week 24. In a post hoc exploratory analysis, there was evidence
Fig. 1 Consort diagram for the study. Patient data listed as missing indicate that data were not collected for a specific time point, although
the patient remained in the study. Withdrawn patients did not provide further study data.
The clinical effectiveness of using a predictive algorithm to guide. . .
M Browning et al.
4
Neuropsychopharmacology (2021) 0:1 – 8
that the improvement in function at 24 weeks may have been
mediated by improvement in anxiety symptoms at 8 weeks.
The effect on symptoms of anxiety and functional outcomes,
but not on symptoms of depression is similar to the effects of the
SSRI sertraline reported in a recent large independent trial in UK
primary care patients [32]. Patients meeting the criteria for entry
into either study were deemed to be depressed or in a depressive
episode, but no severity threshold was applied. Both studies
suggest that, in this group of primary care patients, the change in
depressive symptoms is a relatively insensitive measure of the
effect of SSRI treatment compared with anxiety or functional
measures of outcome. Accordingly, depression symptoms may not
have been the ideal target for our predictive algorithm. An
algorithm trained to predict the change in symptoms of anxiety or
functional recovery may be more useful and will be worth
exploring in future. More generally, the utility of antidepressant
medication is determined by the probability of beneficial and
adverse outcomes, and it may be possible to combine predictive
approaches that are separately sensitive to both. As an example,
there is some early support for the use of pharmacogentic
predictors of gene–drug interactions, which are thought to be
linked to side effects, during initial antidepressant selection and
dosing [33, 34]. Combining this approach with later predictive
assays of treatment outcome, such as the PReDicT test described
here, potentially allows an efficient method for selecting effective
treatments while minimising side effects.
Patients understandably identify functional outcomes as
particularly important measures of treatment success [35].
Overall, the current version of the PReDicT test did bring
forward functional recovery in depressed patients and
improved the subset of symptoms captured by the GAD-7
scale at week 8. The results of the exploratory mediation
analysis suggest a potential mechanistic pathway for this result,
with the initial change in symptoms of anxiety at week
8 significantly impacting the improvement in functional out-
come at week 24. At the population level, anxiety disorders and
particularly generalised anxiety are very commonly comorbid
with depression [36]. Our finding that a reduction in symptoms
of anxiety was associated with enhanced later functioning
strengthens the case for targeting these symptoms during
treatment. One caveat to this interpretation is that the effect of
the intervention on symptoms of anxiety was less robust than
its effect on functional improvement (see sensitivity analyses
in Supplementary Materials) suggesting that a reduction of
anxiety may be one of a number of mechanisms accounting for
the functional improvement. The greater improvement in
function at week 24 became non-significant by week 48; this
was to be expected because the logic of using the PReDicT test
is not that it enhances the underlying efficacy of antidepressant
medication, but rather that it can facilitate more rapid
identification and initiation of more effective treatment. Thus,
use of the test is expected to result in an earlier response to
treatment rather than increase its efficacy.
The motivation for developing personalised approaches to
antidepressant treatment is the ability to rationally select the
treatment that is individually most effective or has fewest side
effects [8]. To date, studies in this area have sought to identify
factors that are associated with future response to treatment
[9–13, 15–17]. However, if personalised approaches are to be
clinically useful, simply predicting the response to treatment is not
sufficient. Rather, the prediction must influence clinician beha-
viour and, ultimately, patient outcome. The PReDicT study is, to
our knowledge, the first robust assessment of this approach for
antidepressant treatment and clearly showed the ability to
influence clinician’s routine. Our finding, that use of the PReDicT
test in primary care settings, across a range of healthcare systems
improved anxiety and functional outcome, therefore, provides
evidence that the selection of antidepressant medication may be
improved in practice by deploying a personalised approach. While
it will remain important to improve the predictive performance of
treatment outcome classifiers, perhaps by combining demo-
graphic, cognitive and biological features [9–13], testing their






France 39 (8%) 37 (8%)
Germany 63 (15%) 67 (14%)
Spain 82 (18%) 82 (18%)
The Netherlands 28 (6%) 26 (6%)
UK 248 (53%) 241 (54%)
Age mean (SD) 38.7 (13.53) 39.21 (14)
Sex, n (%)
Female 285 (62%) 282 (62%)
Male 175 (38%) 171 (38%)
Ethnicity*, n (%)
White 374 (90%) 374 (89%)
Ethnic minority 47 (10%) 42 (11%)
Years of education
mean (SD)
14.14 (3.66) 14.10 (3.47)
Recruited from primary or secondary care
Primary 359 (78%) 345 (76%)








295 (64%) 301 (66%)
Living situation
Living with a spouse
or partner
265 (58%) 244 (54%)
Not living with a
spouse or partner
195 (42%) 209 (46%)
Present or past relationships
Ever been married,
lived with a partner
or had children
319 (69%) 318 (70%)
Never married, lived
with a partner or had
children
141 (31%) 135 (30%)
Family history of depression, n (%)
No 225 (49%) 215 (47%)
Yes 235 (51%) 238 (53%)
QIDS-SR-16
mean (SD)
15.67 (4.53) 15.65 (4.19)
MADRS mean (SD) 28.04 (7.45) 28.07 (7.08)
GAD-7 mean (SD) 13.59 (4.92) 13.77 (4.85)
SAS-SR mean (SD) 63.06 (11.16) 62.88 (11.28)
*A local ethical requirement prevented the collection of data on ethnicity
from patients in France. QIDS-SR-16; Quick Inventory of Depressive
Symptoms, 16-item self-report version (score range 0–27). MADRS;
Montgomery–Åsberg Depression Rating Scale (score range 0–60). GAD-7;
Generalised Anxiety Disorder Assessment, seven-item version (score range
0–21). SAS-SR; Social Adjustment Scale, self-report screener form, T-score
(note a higher score indicates greater impairment, score range 38–90).
Scales are reported as mean (SD).
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clinical utility necessarily requires deployment in randomised
designs such as those reported here.
A number of factors may have limited the overall effectiveness
of the intervention tested in this study. First, the accuracy of the
predictive algorithm was modest at 57.5% (see Supplementary
Materials). It may be possible, and would clearly be desirable, to
develop an algorithm with enhanced predictive properties,
although it will be essential to test any such algorithm in
prospective studies of the target clinical population, such as that
reported here, rather than simply using samples of convenience as
has previously been the norm. Indeed, data from the TaU arm of
this study, which includes a substantial population of patients,
across a number of healthcare systems, with high-quality
cognitive, clinical and demographic data, may facilitate the
development of an improved algorithm. Second, we focused on
effectiveness rather than efficacy, requesting but not requiring
clinicians to alter treatment in response to a prediction of non-
response. The prediction that a patient was not responding only
prompted a change of medication in 65% of cases (see Supple-
mentary Materials), limiting the potential effectiveness of the
intervention. Third, we did not specify how the treatment should
be altered following a prediction of non-response, leaving it to the
treating clinician to decide. As a result, changes in the dose of
antidepressant were by far the commonest alteration made to
treatment, rather than a switch to or augmentation of treatment
with another drug (see Supplementary Materials). Given the doubt
as to the efficacy of dose increases for common antidepressants
[37, 38], this may have limited the impact of the intervention. Last,
the overall response rate in the study was high, being about 10%
higher than in our previous study of primary care patients in the
United Kindom that did not involve weekly self-rating of
symptoms by patients [15]. This raises the possibility that some
aspect of study activity, such as the self-rating of symptoms or
involvement of secondary care services (as occurred in some of
the countries in this study), may have increased response rates in
both groups, in effect adding an aspect of collaborative care to
normal practice [39]. Qualitative data from acceptability and user
experience interviews were collected during the study and will be
reported separately. These data may shed light on how patients’
views of the algorithm influenced their response. Lastly, rando-
misation occurred at the level of the patient rather than the site
and thus the TAU arm may have been influenced by behaviour
learned in the active arm (to increase the dose or switch
antidepressant, for example). All these factors may have served
to weaken the contrast between the two arms of this study.
In summary, our finding that the use of a predictive algorithm
to guide antidepressant treatment improves symptoms of anxiety
and functional outcomes provides initial support for the use of
personalised medicine approaches in the treatment of depression.
This finding illustrates the potential benefit of developing the
insight gained from mechanistic and experimental medicine
studies of treatment mechanisms to build clinical tools that help
patients.
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Table 2. Analyses of measures of depressive symptoms.
PReDicT group TaU group
Categorical outcomes
Time point N % (95% CI) N % (95% CI) Odds ratio (95% CI) P value
QIDS-SR-16 response (primary outcome) Week 8 392 55.91 (48.52, 63.05) 389 51.8 (44.44, 59.08) 1.18 (0.89, 1.56) 0.250
QIDS-SR-16 remission Week 8 392 35.17 (27.69, 43.45) 389 36.16 (28.49, 44.61) 0.96 (0.69, 1.32) 0.792
MADRS response Week 8 378 57.61 (51.47, 63.53) 372 58.44 (52.32, 64.31) 0.97 (0.73, 1.28) 0.812
MADRS remission Week 8 378 29.03 (23.88, 34.78) 372 28.56 (23.48, 34.23) 1.02 (0.76, 1.38) 0.880
Continuous outcomes
Time point N Mean change (95% CI) N Mean change (95% CI) Difference between groups
(95% CI)
P value
QIDS-SR-16 sadness item Week 8 392 −1.34 (−1.46, −1.23) 389 −1.28 (−1.40, −1.16) 0.06 (−0.06, 0.18) 0.295
QIDS-SR-16 restlessness item Week 8 392 −0.53 (−0.62, −0.43) 389 −0.44 (−0.54, −0.34) 0.09 (−0.03, 0.20) 0.133
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Week 48 229 −8.95 (−9.77, −8.13) 233 −8.71 (−9.59, −7.83) 0.24 (−0.54, 1.02) 0.547
Primary outcome highlighted in bold. QIDS-SR-16 quick inventory of depressive symptoms, 16-item self-report version, MADRS Montgomery–Åsberg
Depression Rating Scale. Cut off scores for remission= QIDS-SR-16 ≤ 5, MADRS ≤ 7.
The clinical effectiveness of using a predictive algorithm to guide. . .
M Browning et al.
6
Neuropsychopharmacology (2021) 0:1 – 8
Lundbeck. GD, ACB are employees of P1vital Ltd. RD and JK are
employees of P1vital Products Ltd. GD, JK, CTD own shares in
P1vtial Ltd. JK, RD, CTD and GD own shares in P1vital Products Ltd.
JD reports grants from the DFG, BMBF and Vogel Foundation
during the conduct of the study. He is Co-PI with BioVariance in a
study financed by the Bavarian Secretary of Commerce. GMG
holds shares in P1vital and P1vital Products and has served as
consultant, advisor or CME speaker in the last 3 years for Allergan,
Angelini, Compass pathways, Evapharm, MSD, Janssen, Lundbeck
Otsuka/Takeda, Medscape, Minerva, P1vital, Pfizer, Sage, Servier,
Shire and Sun Pharma. PG has received, over the last 5 years, fees
for presentations at congresses or participation in scientific boards
from Alcediag-Alcen, Angelini, GSK, Janssen, Lundbeck, Otsuka,
SAGE and Servier. CJH has received consultancy fees from P1vital
Products Ltd as well as Janssen, Lundbeck, Sage Pharmaceuticals,
Pfizer, Servier and Zongeixs. AR has received honoraria for lectures
or advisory boards from Medice, Shire/Takeda, Janssen, SAGE,
Servier and neuraxpharm. HGR has received speaking fees from
Lundbeck. BG, RM, AvS, JS, VPS, DJV, ME, AGL, AM, ES and MS
declare no conflict of interest.
AUTHOR CONTRIBUTIONS
MB, JK, GD, CTD, HGR, DJV, AvS, JD, AR, PG, VPS, RM, BG, JS, CJH and GG were
responsible for the initial proposal and securing funding for the trial. MB was the
chief investigator and had overall responsibility for writing the protocol and study
management in the United Kingdom. HGR, DV and AvS had responsibility for the
study in the Netherlands, JD and AR had responsibility for the study in Germany, PG
had responsibility for the study in France and VPS had responsibility for the study in
Spain. MB, JK, GD, CTD, HGR, DJV, AvS, JD, AR, PG, VPS, RM, BG, JS, CJH and GG wrote
the statistical analysis plan. RD, AB, AGL, AM, MS, ES and ME were responsible for data
collection. The analysis was carried out by BG with input from MB, RM and GG. MB
wrote the initial draft of the paper with all authors contributing to the final report.
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41386-021-00981-z.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. WHO. Depression and other common mental disorders. World Health Organization;
2017. http://www.who.int/mental_health/management/depression/prevalence_
global_health_estimates/en/. Accessed March 9, 2020.
2. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment
Health Policy Econ. 2006;9:87–98.
3. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al.
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute
treatment of adults with major depressive disorder: a systematic review and
network meta-analysis. Lancet. 2018;391:1357–66.
4. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al.
Acute and longer-term outcomes in depressed outpatients requiring one or
several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.
5. NICE. CG90 depression in adults: NICE guidance. NICE. 2007. http://www.nice.org.
uk/. Accessed February 14, 2014.
6. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al.
Evidence-based guidelines for treating depressive disorders with antidepressants:
A revision of the 2008 British Association for Psychopharmacology guidelines. J
Psychopharmacol (Oxford). 2015;29:459–525.
7. Saragoussi D, Chollet J, Bineau S, Chalem Y, Milea D. Antidepressant switching
patterns in the treatment of major depressive disorder: a General Practice
Research Database (GPRD) Study. Int J Clin Pr. 2012;66:1079–87. https://doi.org/
10.1111/j.1742-1241.2012.03015.x.
8. Cohen ZD, DeRubeis RJ. Treatment selection in depression. Annu Rev Clin Psy-
chol. 2018;14:209–36. https://doi.org/10.1146/annurev-clinpsy-050817-084746.
9. Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, et al.
Cross-trial prediction of treatment outcome in depression: a machine learning
approach. Lancet Psychiatry. 2016;3:243–50.
10. Dinteren R van, Arns M, Kenemans L, Jongsma MLA, Kessels RPC, Fitzgerald P,
et al. Utility of event-related potentials in predicting antidepressant treatment
response: An iSPOT-D report. Eur Neuropsychopharmacol. 2015;25:1981–90.
11. Etkin A, Patenaude B, Song YJC, Usherwood T, Rekshan W, Schatzberg AF, et al. A
cognitive-emotional biomarker for predicting remission with antidepressant medi-
cations: a report from the iSPOT-D trial. Neuropsychopharmacology. 2015;40:1332–42.
12. Cattaneo A, Ferrari C, Uher R, Bocchio-Chiavetto L, Riva MA, MRC Immu-
noPsychiatry Consortium, et al. Absolute Measurements of Macrophage Migra-
tion Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict
Treatment Response in Depressed Patients. Int J Neuropsychopharmacol.
2016;19:pyw045. https://doi.org/10.1093/ijnp/pyw045.
13. Wu W, Zhang Y, Jiang J, Lucas MV, Fonzo GA, Rolle CE, et al. An electro-
encephalographic signature predicts antidepressant response in major depres-
sion. Nat Biotechnol. 2020:1–9.
14. Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J-F, et al. A sys-
tematic meta-review of predictors of antidepressant treatment outcome in major
depressive disorder. J Affect Disord. 2019;243:503–15.
15. Browning M, Kingslake J, Dourish CT, Goodwin GM, Harmer CJ, Dawson GR.
Predicting treatment response to antidepressant medication using early changes
in emotional processing. Eur Neuropsychopharmacol. 2019;29:66–75. https://doi.
org/10.1016/j.euroneuro.2018.11.1102.
16. de Vries YA, Roest AM, Bos EH, Burgerhof JGM, van Loo HM, de Jonge P. Pre-
dicting antidepressant response by monitoring early improvement of individual
symptoms of depression: individual patient data meta-analysis. Br J Psychiatry.
2019;214:4–10. https://doi.org/10.1192/bjp.2018.122.
17. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, et al.
Comparative effectiveness of biomarkers and clinical indicators for predicting
outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-
MD study. Psychiatry Res. 2009;169:124–31.
18. Harmer CJ, O’Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al.
Effect of acute antidepressant administration on negative affective bias in
depressed patients. Am J Psychiatry. 2009;166:1178–84.
19. Harmer CJ. Serotonin and emotional processing: does it help explain anti-
depressant drug action? Neuropharmacology. 2008;55:1023–8. https://doi.org/
10.1016/j.neuropharm.2008.06.036.
Table 3. Analyses of measures other than symptoms of depression.
PReDicT group TaU group




Week 8 391 −6.12 (−6.83, −5.41) 389 −5.44 (−6.14, −4.74) 0.68 (0.03, 1.32) 0.040
SAS-SR
Week 8 391 −7.60 (−8.57, −6.64) 389 −6.51 (−7.47, −5.54) 1.09 (−0.26, 2.45) 0.112
Week 24 274 −9.70 (−10.79, −8.61) 258 −7.48 (−8.60, −6.36) 2.22 (0.74, 3.70) 0.004
Week 48 228 −10.28 (−11.50, −9.05) 231 −9.60 (−10.81, −8.39) 0.68 (−0.73, 2.08) 0.346
Significant results highlighted in bold. GAD-7 Generalised Anxiety Disorder Assessment, 7-item version, SAS-SR Social Adjustment Scale, self-report screener
form, T-score (note a higher score indicates greater impairment).
The clinical effectiveness of using a predictive algorithm to guide. . .
M Browning et al.
7
Neuropsychopharmacology (2021) 0:1 – 8
20. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ. The effects of
reboxetine on emotional processing in healthy volunteers: an fMRI study. Mol
Psychiatry. 2008;13:1011–20,. https://doi.org/10.1038/sj.mp.4002091.
21. Harmer CJ, Cowen PJ. ‘It’s the way that you look at it’–a cognitive neu-
ropsychological account of SSRI action in depression. Philos Trans R Soc Lond, B,
Biol Sci. 2013;368:20120407 https://doi.org/10.1098/rstb.2012.0407.
22. Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson IM. The effect of
serotonergic and noradrenergic antidepressants on face emotion processing in
depressed patients. J Affect Disord. 2009;118:87–93. https://doi.org/10.1016/j.
jad.2009.01.028.
23. Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, et al. The
effects of using the PReDicT Test to guide the antidepressant treatment of
depressed patients: study protocol for a randomised controlled trial. Trials.
2017;18:558.
24. Tadić A, Wachtlin D, Berger M, Braus DF, van Calker D, Dahmen N, et al. Ran-
domized controlled study of early medication change for non-improvers to
antidepressant therapy in major depression—The EMC trial. Eur Neuropsycho-
pharmacol. 2016;26:705–16.
25. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-
Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating
(QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with
chronic major depression. Biol Psychiatry. 2003;54:573–83.
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to
change. Br J Psychiatry. 1979;134:382–9. https://doi.org/10.1192/bjp.134.4.382.
27. Harmer CJ, Hill SA, Taylor MJ, Cowen PJ, Goodwin GM. Toward a neuropsycho-
logical theory of antidepressant drug action: increase in positive emotional bias
after potentiation of norepinephrine activity. Am J Psychiatry. 2003;160:990–2.
https://doi.org/10.1176/appi.ajp.160.5.990.
28. Gameroff MJ, Wicramaratne P, Weissman MM. Testing the short and screener
versions of the social adjustment scale –self-report (SAS-SR). Int J Methods Psy-
chiatr Res. 2012;21:52–65. https://doi.org/10.1002/mpr.358.
29. Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20:273–97.
https://doi.org/10.1007/BF00994018.
30. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing
generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7.
https://doi.org/10.1001/archinte.166.10.1092.
31. Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, et al. Validation
and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the
general population. Med Care. 2008;46:266–74.
32. Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, et al. The clinical effec-
tiveness of sertraline in primary care and the role of depression severity and
duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised
trial. The Lancet Psychiatry. 2019;6:903–14.
33. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al.
Impact of pharmacogenomics on clinical outcomes in major depressive disorder
in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled
study. J Psychiatr Res. 2019;111:59–67.
34. Zeier Z, Carpenter LL, Kalin NH, Rodriguez CI, McDonlad WM, Wide AS, et al.
Clinical implementation of pharmacogenetic decision support tools for anti-
depressant drug prescribing. AJP. 2018;175:873–86. https://doi.org/10.1176/appi.
ajp.2018.17111282.
35. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu
D. How should remission from depression be defined? The depressed patient’s
perspective. Am J Psychiatry. 2006;163:148–50. https://doi.org/10.1176/appi.
ajp.163.1.148.
36. Judd LL, Kessler RC, PauIus MP, Zeller PV, Wittchen H-U, Kunovac JL. Comorbidity
as a fundamental feature of generalized anxiety disorders: results from the
National Comorbidity Study (NCS). Acta Psychiatr Scandinavica. 1998;98
(s393):6–11. https://doi.org/10.1111/j.1600-0447.1998.tb05960.x.
37. Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of
selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major
depression: a systematic review and dose-response meta-analysis. Lancet Psy-
chiatry. 2019;6:601–9. https://doi.org/10.1016/S2215-0366(19)30217-2.
38. Ruhé HG, Booij J, v Weert HC, Reitsma JB, Franssen EJF, Fransen EJF, et al. Evi-
dence why paroxetine dose escalation is not effective in major depressive dis-
order: a randomized controlled trial with assessment of serotonin transporter
occupancy. Neuropsychopharmacology. 2009;34:999–1010.
39. Katon W, Guico-Pabia CJ. Improving quality of depression care using organized
systems of care: a review of the literature. Prim Care Companion CNS Disord.
2011;13. https://doi.org/10.4088/PCC.10r01019blu.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
The clinical effectiveness of using a predictive algorithm to guide. . .
M Browning et al.
8
Neuropsychopharmacology (2021) 0:1 – 8
